Phase 2 Tuberculosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years old at the time of giving consent
- People weighing between 35 and 100 kg at the screening visit
- People who have given written consent to take part
- People newly diagnosed with pulmonary tuberculosis (TB in the lungs) that is sensitive to the antibiotic rifampicin, confirmed by a specific molecular test (Xpert MTB/RIF Ultra)
- People whose TB diagnosis is supported by a sputum smear test or a qualifying result on the Xpert Ultra test
- People whose chest X-ray shows findings consistent with TB, as assessed by the trial doctor
- People who are able to cough up sputum (mucus from the lungs) on their own
- Women who could become pregnant must be using two approved methods of contraception, or be abstaining from sex
- Men must be using contraception or abstaining from sex for at least 90 days after their last dose
Who may not be able to join:
- People who have received any anti-TB treatment for their current TB episode in the past 60 days
- People who have taken any medication active against TB within the past 3 months
- People who show signs of TB outside the chest area, as judged by the investigator
- People who completed a full course of TB treatment within the past 3 years
- People who have had two or more separate episodes of TB in the past
- People with a significant current or past medical condition that the trial team considers a safety risk
- People living with HIV who are not yet on antiretroviral (HIV) medication, or have been on it for less than 3 months before screening
- People living with HIV whose immune cell count (CD4+) is below 200 cells/uL at screening
- People living with HIV whose virus level in the blood is above 200 copies/mL at screening
- People living with HIV who have AIDS-defining infections or cancers
- People whose blood test results at screening fall outside the acceptable ranges for liver enzymes (AST, ALT, or ALP), bilirubin, kidney function, red blood cells, white blood cells, neutrophils, or platelets (confirm specific values with trial site)
- People who test positive for hepatitis B or hepatitis C
- People with a blood sugar control reading (HbA1c) of 8.0% or higher
- People currently taking or recently having taken immune-suppressing medications, including steroids
- People with significant drug or alcohol use that could affect their safety or ability to follow the trial requirements
- People who are pregnant, breastfeeding, have a positive pregnancy test, or are planning a pregnancy shortly after treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gates MRI, Gates Medical Research Institute
Phone: +1 857 702 2108
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Bactericidal Activity; Safety: SAEs; Safety: TEAEs; Safety: AESIs; Safety: AEs leading to treatment discontinuation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.